Meditope Biosciences Garners $3,600,000 Series A Financing

  • Feed Type
  • Date
    7/27/2013
  • Company Name
    Meditope Biosciences
  • Mailing Address
    301 North Lake Avenue Pasadena, CA 91101
  • Company Description
    Discovered at City of Hope, Meditope’s technology is capable of turning any monoclonal antibody (mAb) into a proprietary, site-specific “Lego-like” system that is able to attach and detach drugs to antibodies without the need for chemical conjugation.
  • Website
    http://www.meditope.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $3,600,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    The company will use the proceeds to accelerate development of its antibody-based cancer products.
  • M&A Terms
  • Venture Investor
    Undisclosed

By posting a comment, you agree to our terms and conditions.